218 related articles for article (PubMed ID: 34311628)
1. Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer.
Noel CW; Keshavarzi S; Forner D; Stephens RF; Watson E; Monteiro E; Hosni A; Hansen A; Goldstein DP; de Almeida JR
Otolaryngol Head Neck Surg; 2022 May; 166(5):877-885. PubMed ID: 34311628
[TBL] [Abstract][Full Text] [Related]
2. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
[TBL] [Abstract][Full Text] [Related]
3. Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer.
Stephens RF; Noel CW; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Mar; 42(3):513-521. PubMed ID: 31762112
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
[TBL] [Abstract][Full Text] [Related]
5. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
7. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
8. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
9. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35).
Sherman AC; Simonton S; Adams DC; Vural E; Owens B; Hanna E
Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):459-67. PubMed ID: 10772298
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties of the Urdu version of the EORTC QLQ-H&N35 (European organization for research and treatment of cancer head and neck module) quality of life tool.
Zahid N; Martins RS; Zahid W; Azam I; Ikram M; Hassan A; Bhamani SS; Jabbar AA; Asad N; Akhtar S; Siddiqui MI; Awan MS; Ahmad K
BMC Psychol; 2022 Aug; 10(1):194. PubMed ID: 35934706
[TBL] [Abstract][Full Text] [Related]
11. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
12. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
14. Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer-specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer.
Jansen F; Snyder CF; Leemans CR; Verdonck-de Leeuw IM
Head Neck; 2016 Apr; 38 Suppl 1():E1493-500. PubMed ID: 27111696
[TBL] [Abstract][Full Text] [Related]
15. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
17. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
18. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
19. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.
Bjordal K; de Graeff A; Fayers PM; Hammerlid E; van Pottelsberghe C; Curran D; Ahlner-Elmqvist M; Maher EJ; Meyza JW; Brédart A; Söderholm AL; Arraras JJ; Feine JS; Abendstein H; Morton RP; Pignon T; Huguenin P; Bottomly A; Kaasa S
Eur J Cancer; 2000 Sep; 36(14):1796-807. PubMed ID: 10974628
[TBL] [Abstract][Full Text] [Related]
20. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]